Expertise in
4
conditions

Dr. Beth Safirstein

Neurology
Velocity Clinical Research Hallandale Beach
911 E Hallandale Beach Blvd, 
Hallandale Beach, FL 
Expertise in
4
conditions
Velocity Clinical Research Hallandale Beach
911 E Hallandale Beach Blvd, 
Hallandale Beach, FL 

Overview

Beth Safirstein is a Neurologist in Hallandale Beach, Florida. Dr. Safirstein is highly rated in 4 conditions, according to our data. Her top areas of expertise are Familial Hemiplegic Migraine, Migraine with Brainstem Aura, Parkinson's Disease, and Movement Disorders.

Her clinical research consists of co-authoring 8 peer reviewed articles and participating in 20 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Neurology

Licenses

Psychiatry & Neurology in FL

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 4 Less Insurance Carriers -

Locations

Velocity Clinical Research Hallandale Beach
911 E Hallandale Beach Blvd, Hallandale Beach, FL 33009

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

18 Clinical Trials

A Phase 1/2, First-Time-in Human (FTiH), Randomized, Observer-blind, Placebo-controlled, Dose Escalation Study to Assess Safety, Reactogenicity and Immunogenicity of a Candidate Cytomegalovirus (CMV) Vaccine Comprising Recombinant Protein and Adjuvant When Administered Intramuscularly in Healthy Adults
A Phase 1/2, First-Time-in Human (FTiH), Randomized, Observer-blind, Placebo-controlled, Dose Escalation Study to Assess Safety, Reactogenicity and Immunogenicity of a Candidate Cytomegalovirus (CMV) Vaccine Comprising Recombinant Protein and Adjuvant When Administered Intramuscularly in Healthy Adults
Enrollment Status: Completed
Publish Date: March 02, 2026
Intervention Type: Biological, Combination product
Study Phase: Phase 1/Phase 2
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: August 29, 2025
Intervention Type: Drug
Study Drug: Donanemab
Study Phase: Phase 3
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Study Evaluating the Safety and Efficacy of Simufilam 100 mg Tablets in Subjects With Mild-to-Moderate Alzheimer's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Study Evaluating the Safety and Efficacy of Simufilam 100 mg Tablets in Subjects With Mild-to-Moderate Alzheimer's Disease
Enrollment Status: Completed
Publish Date: May 25, 2025
Intervention Type: Drug
Study Drug: Simufilam
Study Phase: Phase 3
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3372993 in Participants With Alzheimer's Disease and Healthy Participants
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3372993 in Participants With Alzheimer's Disease and Healthy Participants
Enrollment Status: Completed
Publish Date: March 28, 2025
Intervention Type: Drug
Study Drug: LY3372993
Study Phase: Phase 1
A Randomized , Double Blind, Placebo Controlled, 3-Arm Parallel Design Study to Evaluate the Effects of BPN14770 in Patients With Early Stage Alzheimer's Disease
A Randomized , Double Blind, Placebo Controlled, 3-Arm Parallel Design Study to Evaluate the Effects of BPN14770 in Patients With Early Stage Alzheimer's Disease
Enrollment Status: Completed
Publish Date: February 18, 2025
Intervention Type: Drug
Study Drug: BPN14770
Study Phase: Phase 2
A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of AGB101on Slowing Progression of Mild Cognitive Impairment Due to Alzheimer's Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of AGB101on Slowing Progression of Mild Cognitive Impairment Due to Alzheimer's Disease
Enrollment Status: Completed
Publish Date: May 17, 2024
Intervention Type: Drug
Study Drug: AGB101
Study Phase: Phase 2/Phase 3
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1™ Adjuvant in Adult Participants ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years)
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1™ Adjuvant in Adult Participants ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years)
Enrollment Status: Completed
Publish Date: December 21, 2023
Intervention Type: Biological, Other
Study Drug: SARS-CoV-2 rS/Matrix-M1 Adjuvant
Study Phase: Phase 3
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
Enrollment Status: Completed
Publish Date: November 27, 2023
Intervention Type: Drug
Study Drug: Dihydroergotamine
Study Phase: Phase 3
A Phase 1 Placebo-Controlled, Single- and Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous ACU193 in Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease
A Phase 1 Placebo-Controlled, Single- and Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous ACU193 in Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease
Enrollment Status: Completed
Publish Date: July 19, 2023
Intervention Type: Drug
Study Drug: ACU193
Study Phase: Phase 1
An Open-Label, 12-Month Study to Evaluate the Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
An Open-Label, 12-Month Study to Evaluate the Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
Enrollment Status: Completed
Publish Date: July 03, 2023
Intervention Type: Drug
Study Drug: Dihydroergotamine
Study Phase: Phase 3
View 9 Less Clinical Trials

8 Total Publications

Gefapixant as a P2X3 receptor antagonist treatment for obstructive sleep apnea: a randomized controlled trial.
Gefapixant as a P2X3 receptor antagonist treatment for obstructive sleep apnea: a randomized controlled trial.
Journal: Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine
Published: July 29, 2024
Similar Doctors
Expertise in
19
conditions
Dr. Macarena De La Fuente
Neurology
Expertise in
19
conditions
Dr. Macarena De La Fuente
Neurology

Umhc-Sylvester Comprehensive Cancer Center

1475 NW 12th Ave, 
Miami, FL 
 (14.4 miles away)
305-243-4000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Macarena De La Fuente is a Neurologist in Miami, Florida. Dr. De La Fuente is highly rated in 19 conditions, according to our data. Her top areas of expertise are Glioma, Glioblastoma, Astrocytoma, and Gliomatosis Cerebri.

Expertise in
18
conditions
Dr. Stuart Isaacson
Neurology
Expertise in
18
conditions
Dr. Stuart Isaacson
Neurology

Office

951 NW 13th St Ste 5E, 
Boca Raton, FL 
 (25.0 miles away)
561-392-1818
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Stuart Isaacson is a Neurologist in Boca Raton, Florida. Dr. Isaacson is highly rated in 18 conditions, according to our data. His top areas of expertise are Parkinson's Disease, Movement Disorders, Drug Induced Dyskinesia, and Orthostatic Hypotension.

Expertise in
17
conditions
Dr. Carlos Singer
Neurology
Expertise in
17
conditions
Dr. Carlos Singer
Neurology

Epilepsy Foundation Of Florida

1150 NW 14th St Ste 609, 
Miami, FL 
 (14.3 miles away)
305-243-3320
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Carlos Singer is a Neurologist in Miami, Florida. Dr. Singer is highly rated in 17 conditions, according to our data. His top areas of expertise are Movement Disorders, Parkinson's Disease, Drug Induced Dyskinesia, Tardive Dyskinesia, and Deep Brain Stimulation.

Frequently Asked Questions about Dr. Beth Safirstein

How do I make an appointment with Dr. Beth Safirstein?

You can book an appointment with Dr. Beth Safirstein by calling their office at 954-455-5757. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Beth Safirstein a top-rated expert for Familial Hemiplegic Migraine?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Beth Safirstein is classified as an Advanced expert for Familial Hemiplegic Migraine, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Beth Safirstein specialize in?

While Dr. Beth Safirstein is a Neurology, they have specific expertise in Familial Hemiplegic Migraine, Migraine with Brainstem Aura, and Parkinson's Disease. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Neurology.

Does Dr. Beth Safirstein participate in research or clinical trials?

Yes. Dr. Beth Safirstein has published 8 articles and abstracts on conditions like Familial Hemiplegic Migraine. You can view a list of Dr. Beth Safirstein's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Beth Safirstein accept my insurance?

Dr. Beth Safirstein accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 954-455-5757 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Safirstein's expertise for a condition
ConditionClose
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile